You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Sunrise and Skin Cancer: A Look Into LAG-3 Inhibitors for the Treatment of Melanoma

  • Authors: Susan Schneider, PhD, RN, AOCN; Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP; Hussein Tawbi, MD, PhD; Michele Fierstein
  • CE Released: 5/19/2023
  • Valid for credit through: 5/19/2024
Start Activity

  • Credits Available

    Nurses - 1.25 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for oncology nurses, oncology nurse practitioners (NPs), and other members of the melanoma care team.

The goal of this activity is for learners to be better able to mitigate potential adverse events (AEs) associated with lymphocyte-activation gene 3 (LAG3) inhibitors as well as leverage the patient voice in the care of patients potentially eligible for or already receiving LAG3 inhibitors for metastatic melanoma.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Safety data associated with LAG-3 inhibitors in metastatic melanoma
    • Strategies used to facilitate shared decision-making (SDM) practices in the care of patients with metastatic melanoma potentially eligible for or already receiving LAG-3 inhibitors
  • Have greater competence related to
    • Mitigating potential adverse events experienced by patients receiving LAG-3 inhibitors for metastatic melanoma
  • Demonstrate greater confidence in their ability to
    • Serve as a trusted liaison between the patient and other members of the melanoma treatment team


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Susan Schneider, PhD, RN, AOCN

    Associate Professor Emerita
    Duke University
    Durham, North Carolina
    ONS Past President


    Susan Schneider, PhD, RN, AOCN, has no relevant financial relationships.


  • Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP

    Advanced Practice Registered Nurse
    Department of Melanoma Medical Oncology
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas


    Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP, has no relevant financial relationships.

  • Hussein Tawbi, MD, PhD

    Deputy Chair, Department of Melanoma Medical Oncology
    Co-Director, MD Anderson Brain Metastasis Clinic
    Melanoma Medical Oncology, Investigational Cancer Therapeutics
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas


    Hussein Tawbi, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Boxer Capital; Bristol Myers Squibb Company; Eisai Inc.; Genentech; Iovance; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Medicenna; Merck; Novartis
    Research funding from: Bristol Myers Squibb Company; Dragonfly Therapeutics; Eisai Inc.; EMD Serono; Genentech; GlaxoSmithKline; Merck; Novartis; RAPT Therapeutics

  • Michele Fierstein

    Melanoma patient


    Michele Fierstein, has no relevant financial relationships.


  • Deborah Middleton, MS

    Senior Medical Education Director, Medscape, LLC


    Deborah Middleton, MS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Sunrise and Skin Cancer: A Look Into LAG-3 Inhibitors for the Treatment of Melanoma

Authors: Susan Schneider, PhD, RN, AOCN; Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP; Hussein Tawbi, MD, PhD; Michele FiersteinFaculty and Disclosures

CE Released: 5/19/2023

Valid for credit through: 5/19/2024



  1. American Academy of Dermatology. Skin cancer types: melanoma signs and symptoms. Accessed May 8, 2023.
  2. Chung CM, et al. Skin malignancy initially diagnosed as a benign epidermal cyst. Archi Craniofac Surg. 2020;21:123-126.
  3. Biopsy. Published 2021. Published October 2021. Accessed May 8, 2023.
  4. Huff LS, et al. Defining an acceptable period of time from melanoma biopsy to excision. Dermatol Rep. 2012;4:4-7.
  5. Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208-250.
  6. Woźniak K, et al. Cancer: a family at risk. Menopause Rev. 2014;13:253-261.
  7. Choosing a doctor for your cancer care. Published March 2021. Accessed May 8, 2023.
  8. Balogh EP, et al. Patient-centered cancer treatment planning: improving the quality of oncology care. Summary of an institute of medicine workshop. The Oncol. 2011;16:1800-1805.
  9. American Cancer Society. How treatment is planned and scheduled. Accessed May 8, 2023.
  10. What oncologists think about when recommending a cancer treatment plan. Published March 1, 2022. Accessed May 8, 2023.
  11. National Comprehensive Cancer Network (NCCN). Melanoma cutaneous (Version 3.2022). 2022. Accessed May 8, 2023.
  12. Eggen AM, et al. Value of screening and follow-up brain MRI scans in patients with metastatic melanoma. Cancer Med. 2021;10:8395-8404.
  13. Switzer B, et al. Managing metastatic melanoma in 2022: a clinical review. J Clin Oncol Pract. 2022;18:335-351.
  14. Kakish HH, et al. Trends in melanoma phase 3 clinical trials since 2010: is there hope for advanced melanoma therapies beyond approved treatment mechanisms? Cancers. 2022;14:1-16.
  15. Tawbi HA, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24-34.
  16. Melanoma: about clinical trials. Published December 2021. Accessed May 8, 2023.
  17. Reynolds RB, et al. The role of advanced practice providers in interdisciplinary oncology care in the united states. Chin Clin Oncol. 2016;5:1-6.
  18. Steinberg H. Oncology nurse coordinators in clinical trials – shaking up the melanoma team. 2020;7:250-254.
  19. Rieger PT. Role of the oncology nurse. In: Kufe DW, et al (eds). 6th ed. Holland-Frei Cancer Medicine; Hamilton (ON): BC Decker;2003.
  20. Palos GR, et al. Patients, family caregivers, and patient navigators. Cancer. 2011;117:3592-3602.
  21. Berry LL, et al. Supporting the supporters: what family caregivers need to care for a loved one with cancer. J Oncol Pract. 2016;13:36-41.
  22. United States Food and Drug Administration. Informed consent for clinical trials. Updated January 4, 2018. Accessed May 8, 2023.
  23. Banja JD, et al. Am J Bioeth. Enhancing informed consent in clinical trials and exploring resistances to disclosing adverse clinical trial results. 2009;9:39-41.
  24. Mansky C. Navigating uncertainty in immunotherapy regimens. N Engl J Med. 2023;2:1-3.
  25. Brahmer JR, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:1-33.
  26. National Comprehensive Cancer Network (NCCN). Management of immunotherapy-related toxicities (Version 2.2023). 2023. Accessed May 15, 2023.
  27. Rauwerdink DJW, et al. Mixed response to immunotherapy in patients with metastatic melanoma. Ann Surg. 2020;27:3488-2497.
  28. Humbert O, et al. Dissociated response in metastatic cancer: an atypical pattern brought into the spotlight with immunotherapy. Front Oncol. 2020;10:1-7.
  29. DeBord LC, et al. Social media in dermatology: clinical relevance, academic value, and trends across platforms. J Dermatol Treat. 2018;30:511-518.
  30. Maganty N, et al. Social media as a platform for information and support for melanoma patients: analysis of melanoma facebook groups and pages. JMIR Dermatol. 2018;1:1-5.
  31. Rodin G, et al. Clinican-patient communication: evidence-based recommendations to guide practice in cancer. Curr Oncol. 2009;16:42-49.
  32. Yassine F, et al. Chapter 15 – patient resources in a cancer center. In: Aljurf A, et al (eds). The Comprehensive Cancer Center. The Author(s); 2022;145-155.
  33. Taberna M, et all The multidisciplinary team (MDT) approach and quality of care. Front Oncol. 2020;10:1-16.
  34. Zhang L, et al. Follow-up care for patients receiving immune checkpoint inhibitors. 2021;8:596-603.
  35. Oncology Nursing Society. Voice website. Wiley K. Nursing considerations for melanoma survivorship care. ONS Voice. 2021.
« Return to: Sunrise and Skin Cancer: A Look Into LAG-3 Inhibitors for the Treatment of Melanoma
  • Print